NRX Pharmaceuticals, Inc. (NRXP): R&D Expense
$3.78M
Year ended 2025-12-31
$5.41M
Trailing 12 months to 2026-06-30
-39.5%
3-year compound annual growth
-18.7%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.78M | -39.1% | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | $6.20M | -53.6% | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | $13.37M | -21.5% | 2025-03-14, From 2023-01-01 |
| 2022-12-31 | $17.03M | -15.9% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $20.26M | +90.7% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $10.62M | n/a | 2022-03-31, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $3.78M | -39.1% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.04M | -84.4% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $28.79M | -17.5% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $20.20M | -24.3% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $3.65M | -3.1% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $54.97M | +39.6% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $12.04M | +48.0% |
| Neuphoria Therapeutics Inc. (NEUP) | 2025-06-30 | $9.01M | -4.4% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $8.58M | +16.8% |
Compare NRXP, ATXI, NWBO, RANI side by side · Screen every company in Pharmaceutical Preparations ↗